<DOC>
	<DOCNO>NCT00317408</DOCNO>
	<brief_summary>RATIONALE : Giving combination chemotherapy total-body irradiation peripheral stem cell transplant use patient 's donor 's stem cell , help stop growth cancer cell patient 's immune system reject stem cell . When stem cell infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Giving combination chemotherapy total-body irradiation follow stem cell transplant may effective treatment anaplastic large cell lymphoma . PURPOSE : This clinical trial study well combination chemotherapy follow stem cell transplant work treat young patient progressive relapse anaplastic large cell lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Followed By Stem Cell Transplant Treating Young Patients With Progressive Relapsed Anaplastic Large Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Improve probability event-free survival child adolescent early progression anaplastic large cell lymphoma ( ALCL ) and/or relapse ALCL CD3-positive immunophenotype treat reinduction combination chemotherapy follow allogeneic autologous stem cell transplantation . - Determine whether condition regimen comprise carmustine , etoposide phosphate , cytarabine , melphalan ( BEAM ) ( without total body irradiation ) autologous stem cell transplantation effective treatment patient relapse CD3-negative ALCL occur intensive phase treatment . - Determine impact vinblastine patient late relapse CD3-negative ALCL receive vinblastine frontline therapy . Secondary - Determine overall survival treatment-related mortality patient treat regimen . - Determine acute long-term toxicity patient treat regimen . - Determine rate acute chronic graft-vs-host disease patient treat allogeneic stem cell transplantation . OUTLINE : This multicenter , prospective , nonrandomized study . Patients stratify accord time initial diagnosis progression/relapse , immunophenotype lymphoma cell ( CD3-positive + v CD3-negative ) , stem cell donor availability ( matched sibling donor vs 9/10 10/10 match unrelated donor ) , vinblastine frontline therapy ( yes v ) . - Group 1 ( early progression ) : Patients receive 1 course ICM chemotherapy follow 1 course ICI chemotherapy . - ICM chemotherapy : Patients receive methotrexate , cytarabine , prednisolone intrathecally ( IT ) day 1 , mitoxantrone hydrochloride IV 5 hour day 1 2 , carboplatin IV continuously day 2-5 ifosfamide IV continuously day 2-6 . - ICI chemotherapy : Patients receive methotrexate , cytarabine , prednisolone intrathecally day 1 , idarubicin IV 4 hour day 1 2 , carboplatin IV continuously day 2-5 , ifosfamide IV continuously day 2-6 . Patients proceed allogeneic stem cell transplantation . - Group 2 ( relapsed disease CD3-positive lymphoma cell ) : Patients stratify accord stem cell donor availability ( yes v ) . - Available donor : Patients receive 2 course CC chemotherapy proceed allogeneic stem cell transplantation . - Unavailable donor : Patients receive 2 course CC chemotherapy comprise dexamethasone orally IV day 1-5 , vindesine IV day 1 , cytarabine IV 3 hour day 1 2 , etoposide phosphate IV 2 hour day 3-5 , methotrexate , cytarabine , prednisolone IT day 5 . Patients receive 1 course CVA chemotherapy comprise oral lomustine day 1 , vinblastine IV day 1 , 8 , 15 , 22 , cytarabine IV 1 hour day 1-5 . Patients undergo leukapheresis collection autologous peripheral blood stem cell first and/or second course CC chemotherapy . Patients proceed autologous stem cell transplantation . - Group 3 ( relapsed disease , CD3-negative immunophenotype , receive vinblastine frontline therapy ) : Patients receive 2 course CC chemotherapy 1 course CVA chemotherapy describe . Patients undergo leukapheresis collection autologous peripheral blood stem cell ( PBSC ) first and/or second course CC chemotherapy . Patients proceed autologous stem cell transplantation . - Group 4 ( late relapse , CD3-negative immunophenotype , receive vinblastine frontline therapy ) : Patients receive vinblastine IV weekly 24 month . Patients disease progression relapse disease vinblastine therapy undergo treatment group 3 . - Autologous stem cell transplantation ( SCT ) : Patients receive condition regimen comprise carmustine IV 1 hour day -7 , etoposide phosphate IV 1 hour cytarabine IV 30 minute day -6 -3 , melphalan IV 15 minute day -2 . Patients undergo autologous SCT day 0 . - Allogeneic SCT : Beginning 4-6 week start last chemotherapy course , patient receive 1 follow conditioning regimen base age : - Patients &gt; 2 year age undergo total body irradiation day -7 -5 receive thiotepa IV 1 hour day -4 etoposide IV 4 hour day -3 . Patients undergo allogeneic SCT day 0 . - Patients â‰¤ 2 year age receive oral busulfan 4 time daily day -8 -5 , thiotepa IV 1 hour twice day -4 , etoposide phosphate IV 4 hour day -3 . Patients undergo allogeneic SCT day 0 . Patients undergo SCT unrelated donor also receive antithymocyte globulin IV 4 hour day -3 -1 . All patient receive graft-versus-host ( GVHD ) prophylaxis describe . - GVHD prophylaxis : GVHD prophylaxis administer per donor status . - Matched sibling donor : Patients receive cyclosporine IV 2 hour orally day -1 60 follow taper . - 10/10 9/10 match unrelated donor : Patients receive cyclosporine IV 2 hour orally day -1 100 follow taper , methotrexate IV day 1 , 3 , 6 , leucovorin calcium IV day 2 , 4 , 7 . - Mismatched donor : Patients receive GVHD prophylaxis , however , CD3-positive lymphocyte extract donor stem cell . After completion study treatment , patient follow periodically 10 year . PROJECTED ACCRUAL : A total 96 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vindesine</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm anaplastic large cell lymphoma ( ALCL ) Progressive disease OR first relapse No second subsequent relapse ALCL Slides available national central pathology review Availability 1 follow ( allogeneic stem cell transplantation ) : HLAidentical match sibling donor 10/10 HLAmatched nonsibling donor ( relate unrelated ) 9/10 HLAmatched nonsibling donor ( 1antigenmismatched relate unrelated donor ) &lt; 9/10 HLAmismatched donor ( relate unrelated ) Stem cell may obtain unmanipulated bone marrow peripheral blood stem cell filgrastim ( GCSF ) stimulation PATIENT CHARACTERISTICS : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Adequate hepatic , renal , cardiac function No HIV infection AIDS No severe immunodeficiency No prior malignancy No preexist disease condition prohibit study treatment PRIOR CONCURRENT THERAPY : At least 2 month since prior chemotherapy radiotherapy No significant pretreatment first relapse No prior organ transplantation No concurrent participation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>recurrent childhood anaplastic large cell lymphoma</keyword>
	<keyword>stage III childhood anaplastic large cell lymphoma</keyword>
	<keyword>stage IV childhood anaplastic large cell lymphoma</keyword>
</DOC>